EX-99.1

Exhibit 99.1

 

LOGO

Corbus Pharmaceuticals Reports 2015 First Quarter Financial Results and Provides Business Update

-First quarter marked by significant progress on operational, clinical and regulatory milestones-

-Company expects to commence Phase 2 clinical studies of Resunab in scleroderma in 2Q 2015 and cystic fibrosis in 3Q 2015-

Norwood, MA (May 13, 2015)Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (the “Company”), a clinical stage drug development company targeting rare, life-threatening chronic inflammatory and fibrotic diseases, announced today its financial results for the quarter ended March 31, 2015.

The Company also provided an update to its corporate progress and the clinical status for Resunab™, its novel synthetic oral drug for the treatment of chronic inflammation and fibrosis associated with cystic fibrosis (“CF”), diffuse cutaneous systemic sclerosis (“scleroderma”) and other chronic inflammatory-fibrotic diseases.

Recent Corporate Highlights

 

    Received a $5 million development award from Cystic Fibrosis Foundation Therapeutics (“CFFT”) to advance Resunab into a Phase 2 clinical trial for CF;

 

    Commenced trading of the Company’s common stock on The Nasdaq Capital Market under ticker symbol CRBP;

 

    Submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for a Phase 2 clinical trial of Resunab in 70 adults with CF;

 

    Received clearance from the FDA to initiate Phase 2 clinical trial with Resunab in 36 individuals with diffuse cutaneous systemic scleroderma; and

 

    Presented positive data demonstrating that Resunab significantly decreases fibrotic response and exerts potent anti-fibrotic effects in a preclinical model of lung fibrosis.

“I am very pleased with the progress and milestones achieved so far in 2015,” stated Yuval Cohen, Ph.D., Chief Executive Officer of the Company. “Moving forward, we are committed to adding to this positive momentum and believe Resunab has the potential to be an impactful therapy for individuals suffering from these rare chronic inflammatory and fibrotic diseases.”

Expected Near-Term Milestones

 

    Initiate the Phase 2 clinical study of Resunab for the treatment of scleroderma in the second quarter of 2015;

 

    Launch the Phase 2 study of Resunab for the treatment of CF in the next 90 days, pending FDA clearance of the IND and the clinical protocol;

 


LOGO

 

    File for an EU Investigational Medicinal Products authorization for Resunab with the European Medicines Agency in the third quarter of 2015;

 

    File the Resunab application for U.S. and European Orphan Drug Designation for the treatment of both CF and scleroderma in the third quarter of 2015; and

 

    Present additional data at upcoming peer-reviewed scientific conferences on the biological properties of Resunab and its unique mechanism of action for resolving inflammation in CF.

Summary of Financial Results for First Quarter 2015

For the quarter ended March 31, 2015, the Company reported a net loss of approximately $1,536,000, or a net loss per diluted share of $0.06, compared to a net loss of approximately $116,000, or a net loss per diluted share, of $0.02 for the quarter ended March 31, 2014. The increase in the net loss for the quarter ended March 31, 2015 is attributable to a ramp up of the Company’s operations to support the upcoming clinical trials in scleroderma and cystic fibrosis and the costs associated with being a public company. The Company ended the quarter with approximately $4,972,000 of cash and cash equivalents.

About Resunab™

Resunab™ is a novel synthetic oral drug with unique activity that has been shown to resolve inflammation and pro-fibrotic processes. Pre-clinical models and Phase 1 clinical studies have shown Resunab to have a favorable safety profile coupled with promising potency in pre-clinical models of inflammation and fibrosis. Resunab binds to the CB2 receptor on immune cells in the periphery and triggers resolution of inflammation and reduction of pro-inflammatory pathways, in effect turning chronic inflammation “off” without causing immunosuppression.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. Our lead product candidate Resunab™ is a novel oral drug that resolves chronic inflammation and pro-fibrotic processes. Resunab is scheduled to commence Phase 2 clinical trials for the treatment of cystic fibrosis and diffuse cutaneous systemic sclerosis (scleroderma) in 2015. For more information, please visit www.CorbusPharma.com.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

CORBUS PHARMACEUTICALS Holdings Inc.

100 River Ridge Drive Norwood MA 02062 | Tel +1 (617) 963-0100 | Fax +1 617 795 2189 | www.corbuspharmaceuticals.com


LOGO

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact

Jenene Thomas

Investor Relations and Corporate Communications Advisor

Jenene Thomas Communications, LLC

Phone: +1 (908) 938-1475

Email: jenene@jenenethomascommunications.com

Media Contact

David Schull or Marissa Goberdhan

Russo Partners, LLC

Phone: +1 (858) 717-2310

Email: david.schull@russopartnersllc.com

Email: marissa.goberdhan@russopartnersllc.com

Source: Corbus Pharmaceuticals Holdings, Inc.

 

 

 

CORBUS PHARMACEUTICALS Holdings Inc.

100 River Ridge Drive Norwood MA 02062 | Tel +1 (617) 963-0100 | Fax +1 617 795 2189 | www.corbuspharmaceuticals.com


LOGO

 

Corbus Pharmaceuticals Holdings, Inc.

Condensed Consolidated Statement of Operations

(Unaudited)

 

     For the Three Months Ended
March 31,
 
     2015     2014  

Operating expenses:

    

Research and development

   $ 723,430      $ 61,917   

General and administrative

     811,869        43,728   
  

 

 

   

 

 

 

Total operating expenses

  1,535,299      105,645   
  

 

 

   

 

 

 

Operating loss

  (1,535,299   (105,645

Other expense:

Interest expense

  (979   (11,163

Interest income

  560      45   

Change in fair value of warrant liability

  —        1,518   

Foreign currency exchange loss

  —        (734
  

 

 

   

 

 

 

Other expense, net

  (419   (10,334
  

 

 

   

 

 

 

Net loss

$ (1,535,718 $ (115,979
  

 

 

   

 

 

 

Net loss per share, basic and diluted

$ (0.06 $ (0.02
  

 

 

   

 

 

 

Weighted average number of common shares outstanding, basic and diluted

  25,871,796      6,964,788   
  

 

 

   

 

 

 

 

CORBUS PHARMACEUTICALS Holdings Inc.

100 River Ridge Drive Norwood MA 02062 | Tel +1 (617) 963-0100 | Fax +1 617 795 2189 | www.corbuspharmaceuticals.com


LOGO

 

Corbus Pharmaceuticals Holdings, Inc.

Condensed Consolidated Balance Sheet

 

     March 31,
2015
    December 31,
2014
 
     (Unaudited)        

ASSETS

    

Current assets:

    

Cash and cash equivalents

   $ 4,971,466      $ 6,262,445   

Prepaid expenses

     210,751        270,556   
  

 

 

   

 

 

 

Total current assets

  5,182,217      6,533,001   
  

 

 

   

 

 

 

Restricted cash

  13,730      13,728   

Property and equipment, net

  50,400      54,044   
  

 

 

   

 

 

 

Total assets

$ 5,246,347    $ 6,600,773   
  

 

 

   

 

 

 

LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$ 188,298    $ 344,160   

Accrued expenses

  293,989      249,491   

Notes payable-current

  72,487      144,389   
  

 

 

   

 

 

 

Total current liabilities

  554,774      738,040   
  

 

 

   

 

 

 

Total liabilities

  554,774      738,040   
  

 

 

   

 

 

 

Commitments and Contingencies

Stockholders’ equity

Preferred Stock $0.0001 par value: 10,000,000 share authorized, no shares issued and outstanding at March 31, 2015 and December 31, 2014

  —        —     

Common stock, $0.0001 par value; 150,000,000 shares authorized, 26,003,304 and 25,938,332 shares issued and outstanding at March 31, 2015 and December 31, 2014

  2,600      2,594   

Additional paid-in capital

  10,651,766      10,287,214   

Accumulated deficit

  (5,962,793   (4,427,075
  

 

 

   

 

 

 

Total stockholders’ equity

  4,691,573      5,862,733   
  

 

 

   

 

 

 

Total liabilities, preferred stock and stockholders equity

$ 5,246,347    $ 6,600,773   
  

 

 

   

 

 

 

###

 

CORBUS PHARMACEUTICALS Holdings Inc.

100 River Ridge Drive Norwood MA 02062 | Tel +1 (617) 963-0100 | Fax +1 617 795 2189 | www.corbuspharmaceuticals.com